Externally validated digital decision support tool for time-to-osteoradionecrosis risk-stratification using right-censored multi-institutional observational cohorts
- PMID: 40222595
- PMCID: PMC12085279
- DOI: 10.1016/j.radonc.2025.110890
Externally validated digital decision support tool for time-to-osteoradionecrosis risk-stratification using right-censored multi-institutional observational cohorts
Abstract
Background: Existing studies on osteoradionecrosis of the jaw (ORNJ) have primarily used cross-sectional data, assessing risk factors at a single time point. Determining the time-to-event profile of ORNJ has important implications to monitor oral health in head and neck cancer (HNC) long-term survivors.
Methods: Data were retrospectively obtained for a clinical observational cohort of 1129 patients (198 ORNJ cases) with HNC treated with radiotherapy (RT) at The University of Texas MD Anderson Cancer Center. A Weibull Accelerated Failure Time model was trained on previously identified dosimetric, clinical and demographic predictors. External validation was performed using an independent cohort of 265 patients (92 ORNJ cases) treated at Guy's and St. Thomas' Hospitals. To facilitate clinical implementation of the model, an online graphical user interface (GUI) was developed, including formal stakeholder usability testing.
Results: Our model identified that gender (males), pre-RT dental extractions and D25% were associated with a 38 %, 27 % and 12 % faster onset of ORNJ, respectively, with adjusted time ratios of 0.62 (p = 0.11), 0.73 (p = 0.13) and 0.88 (p < 0.005). The model demonstrated strong internal calibration (integrated Brier score of 0.133, D-calibration p-value 0.998) and optimal discrimination at 72 months (Harrell's C-index of 0.72).
Conclusion: This study is the first to demonstrate a direct relationship between radiation dose and the time to ORNJ onset, providing a novel characterization of the impact of delivered dose and patient-related factors not only on the probability of a late effect (ORNJ), but the conditional risk during survivorship.
Keywords: Decision support tool; Head and neck cancers; Normal tissue complication prediction; Osteoradionecrosis of the jaw; Radiation-induced toxicity; Radiotherapy; Time-to-event prediction models.
Copyright © 2025. Published by Elsevier B.V.
Conflict of interest statement
Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: CDF has received unrelated grant support from Elekta AB and holds unrelated patents licensed to Kallisio, Inc. (US PTO 11730561) through the University of Texas, from which they receive patent royalties. CDF has also received unrelated travel and honoraria from Elekta AB, Philips Medical Systems, Siemens Healthineers/Varian, and Corewell Health. Additionally, CDF has served in an unpaid advisory capacity for Siemens Healthineers/Varian and has served on the guidelines/scientific committee for Osteoradionecrosis for the American Society of Clinical Oncology. VCS is a consultant and equity holder in Femtovox Inc and a consultant for PDS Biotechnology. KAW serves as an Editorial Board Member for Physics and Imaging in Radiation Oncology. The authors declare that no other competing interests exist.
Figures









Similar articles
-
Mandibular dose-volume predicts time-to-osteoradionecrosis in an actuarial normal-tissue complication probability (NTCP) model: External validation of right-censored clinico-dosimetric and competing risk application across international multi-institutional observational cohorts and online graphical user interface clinical support tool assessment.medRxiv [Preprint]. 2024 Aug 20:2024.08.20.24312311. doi: 10.1101/2024.08.20.24312311. medRxiv. 2024. PMID: 39228724 Free PMC article. Preprint.
-
Comparison of Two Modern Survival Prediction Tools, SORG-MLA and METSSS, in Patients With Symptomatic Long-bone Metastases Who Underwent Local Treatment With Surgery Followed by Radiotherapy and With Radiotherapy Alone.Clin Orthop Relat Res. 2024 Dec 1;482(12):2193-2208. doi: 10.1097/CORR.0000000000003185. Epub 2024 Jul 23. Clin Orthop Relat Res. 2024. PMID: 39051924
-
Effect of preradiation dental intervention on incidence of osteoradionecrosis in patients with head and neck cancer: A systematic review and meta-analysis.J Am Dent Assoc. 2022 Oct;153(10):931-942.e32. doi: 10.1016/j.adaj.2022.06.003. Epub 2022 Aug 18. J Am Dent Assoc. 2022. PMID: 35985883
-
International Expert-Based Consensus Definition, Classification Criteria, and Minimum Data Elements for Osteoradionecrosis of the Jaw: An Interdisciplinary Modified Delphi Study.Int J Radiat Oncol Biol Phys. 2025 Jun 1;122(2):341-354. doi: 10.1016/j.ijrobp.2024.12.017. Epub 2025 Jan 16. Int J Radiat Oncol Biol Phys. 2025. PMID: 39826846 Free PMC article.
-
The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation.Health Technol Assess. 2007 Nov;11(45):iii-iv, ix-221. doi: 10.3310/hta11450. Health Technol Assess. 2007. PMID: 17999840
References
-
- Habib S; Sassoon I; Thompson I; Patel V Risk Factors Associated with Osteoradionecrosis. Oral Surgery 2021, 14 (3), 227–235. 10.1111/ors.12597. - DOI
-
- MD Anderson Head and Neck Cancer Symptom Working Group. Dose-Volume Correlates of Mandibular Osteoradionecrosis in Oropharynx Cancer Patients Receiving Intensity-Modulated Radiotherapy: Results from a Case-Matched Comparison. Radiother Oncol 2017, 124 (2), 232–239. 10.1016/j.radonc.2017.06.026. - DOI - PMC - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical